Stocks · News reference
Filed: 2026-09-14 AccNo: 0002019410-26-000061 Size: 187 KB Item 7.01: Regulation FD Disclosure
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Revvity shares surged 9.1% to $140.19 following upbeat commentary on AI-driven demand for research tools, improved order backlog, and a planned acquisition of Human Cell Design. The company expects quarterly EPS of $1.28 (+8.5% YoY) and revenues of $702.56M (+0.5% YoY). However, consensus EPS estimates have been marginally revised lower over the past 30 days, which could limit further price appreciation.
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients predicted to benefit